An object is to provide a peptide gelling agent which gels under physiological conditions and which has a relatively short chain length, and a sustained-release gel based on it. Provided is a hydrogelling self-assembling peptide comprising one or two core peptides consisting of an amino acid sequence represented by the following formula: Xaa-Yaa-Zaa-Yaa-Xaa-Yaa-Zaa-Yaa-Xaa, wherein Xaa is independently Ile or Met, Yaa is independently Asp, Glu, Lys, or Arg, and Zaa is independently Ala or Gly, and wherein the full length of the amino acid sequence constituting said self-assembling peptide is 25 amino acids or less.

The present invention relates to a hydrogel precursor formulation, its process of production as well as a kit comprising said formulation and a method of production of a hydrogel using said formulation. The precursor formulation comprises at least one structural compound, preferably vinyl sulfone (acrylated branched) poly(ethylene glycol), and at least one linker compound, preferably a peptide with two cysteines, wherein said structural compound and said linker compound are polymerizable by a selective reaction between a nucleophile and a conjugated unsaturated bond or group. The precursor formulation is in the form of a powder.

A method for producing a three-dimensional cell structure includes preparing a mixture of a cationic substance, an extracellular matrix component, a polyelectrolyte, and a cell population including endothelial cells and mouse-derived stromal cells, which exclude mouse-derived endothelial cells, collecting a cell aggregate from the mixture, and culturing a collected cell aggregate to obtain a three-dimensional cell structure.

The present invention relates to the field of implants for the formation/regeneration of lymph nodes. In particular, the present invention relates to an implant comprising a biodegradable scaffold and lymph node fragments immobilized therein and/or thereon, to a method of manufacturing such an implant and to uses of such an implant.

The invention relates to a method for obtaining endothelial cells from human pluripotent stem cells.

The present disclosure provides multicellular culture models for the study of neuroinflammation, such as to identify novel targets, biomarkers, and therapeutic agents for the diagnosis, prognosis, and treatment of neurodegenerative diseases. Further provided herein are assays for studying neuroinflammation using the present cell culture models.

A method for extracting differentiated cells from a cell population comprising undifferentiated cells after induction of the differentiation of pluripotent stem cells. A method for extracting differentiated cells from a cell population, comprising the following steps: (1) a step of introducing, into a cell population, mRNA comprising a marker gene operably linked to the target sequence of miRNA specifically expressed in pluripotent stem cells; and (2) a step of extracting cells in which the marker gene has been translated.

Provided herein are hydrogel cell matrices, hydrogel cell matrix systems for the support, growth, and differentiation of a stem cell or progenitor cell and methods for making such hydrogel cell matrices.

Devices, systems, and their methods of use, for generating droplets are provided. One or more geometric parameters of a microfluidic channel can be selected to generate droplets of a desired and predictable droplet size.

The present invention relates to a method for culturing neural stem cells into spheroids, the method including: culturing neural stem cells in a culture vessel coated with a protein containing a VGVPG pentapeptide and an RGD integrin receptor ligand; and isolating the neural stem cells that are aggregated and formed into spheroids during the culturing.